<DOC>
	<DOC>NCT02245997</DOC>
	<brief_summary>The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.</brief_summary>
	<brief_title>Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Patients must have a diagnosis of neuroblastoma (International Classification of Disease for Oncology [ICDO] morphology 9500/3) confirmed by MSKCC pathologic review Patients must have highrisk neuroblastoma as defined by the COG Risk Stratification Schema o Patients with International agreement on staging (INSS) stage 4 are eligible with the following: MYCN amplification, regardless of age or additional biologic features Age &gt;18 months, regardless of biologic features OR Age 1218 months, with any of the 3 following unfavorable biologic OR features: MYCN amplification, unfavorable pathology, and/or DNA index = 1 o Patients with INSS stage 3 are eligible with the following: MYCN amplification, regardless of age or additional biologic features OR Age &gt; 18 months with unfavorable pathology, regardless of MYCN status o Patients with INSS stage 2a or 2b are eligible with the following: MYCN amplification, regardless of age or additional biologic features o Patients with INSS stage 4s are eligible with the following: MYCN amplification, regardless of additional biologic features Patients must have undergone chemotherapy and surgery for highrisk neuroblastoma prior to enrollment on trial. Age at time of enrollment of ≥1 year and ≤18 years Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start. Female patients who are lactating must agree to stop breastfeeding. Sexually active patients of childbearing potential must agree to use effective contraception. Patients with gross residual tumor after surgical resection Patients who have received prior radiotherapy at or adjacent to the primary tumor bed Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Reduced-dose Radiotherapy</keyword>
	<keyword>14-186</keyword>
</DOC>